Eric J. Suba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eric J. Suba has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Stephen S. Raab
University of Mississippi Medical Center, Jackson, MS, United States
18 shared publicationsStephen S Raab
Memorial University of Newfoundland Saint John's, Newfoundland, Canada
6 shared publicationsMy Linh D. Huynh
Kaiser Permanente Medical Center, 4141 Geary Boulevard, San Francisco, California
4 shared publicationsAmber D. Donnelly
3 shared publicationsLisa M. Furia
3 shared publicationsNguyen Chan Hung
Ho Chi Minh City Cancer Center, Cancer Society of Vietnam, Ho Chi Minh City, Vietnam
3 shared publications
Latest Publications
- 15 October 2026
- Published by Elsevier in The Lancet
- Vol. 408 (10564) , 1549-1550
WHO should adjust its cervical cancer plan
- 15 October 2026
- Published by Elsevier in The Lancet
- Vol. 408 (10564) , 1549-1550
WHO should adjust its cervical cancer plan
- Open Access
- 26 April 2024
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 19 (1) , 1-4
Researchers should no longer delay implementation of Pap screening in low and middle income countries pending research into novel screening approaches
A study coordinated by Groesbeck Parham and Mark Schiffman describes a novel approach to single-visit, point-of-care cervical screening and triage for low and middle income countries (LMICs) that uses an HPV screening test that is not affordable in LMICs combined with a triage test that is not available at the point of care. Pap smears are feasible, affordable, and well-suited for single-visit, point-of-care cervical screening and triage in LMICs. Research into a discredited cervical screening test, funded by the US National Cancer Institute, contributed to at least 500,000 preventable cervical cancer deaths by delaying implementation of Pap screening throughout India for 18 years. Researchers should no longer delay implementation of Pap screening in LMICs pending research into novel screening approaches. Instead, researchers should prioritize cervical screening approaches that will save as many lives as quickly as possible in LMICs. To that end, Parham et al. should implement good-quality, single-visit, point-of-care Pap smear screening in LMICs until better-quality, single-visit, point-of-care HPV screening becomes widely affordable in LMICs.
- 26 April 2024
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 19 (1) , 1-4
Open AccessResearchers should no longer delay implementation of Pap screening in low and middle income countries pending research into novel screening approaches
A study coordinated by Groesbeck Parham and Mark Schiffman describes a novel approach to single-visit, point-of-care cervical screening and triage for low and middle income countries (LMICs) that uses an HPV screening test that is not affordable in LMICs combined with a triage test that is not available at the point of care. Pap smears are feasible, affordable, and well-suited for single-visit, point-of-care cervical screening and triage in LMICs. Research into a discredited cervical screening test, funded by the US National Cancer Institute, contributed to at least 500,000 preventable cervical cancer deaths by delaying implementation of Pap screening throughout India for 18 years. Researchers should no longer delay implementation of Pap screening in LMICs pending research into novel screening approaches. Instead, researchers should prioritize cervical screening approaches that will save as many lives as quickly as possible in LMICs. To that end, Parham et al. should implement good-quality, single-visit, point-of-care Pap smear screening in LMICs until better-quality, single-visit, point-of-care HPV screening becomes widely affordable in LMICs.
- Open Access
- 12 June 2023
- Published by BMJ in BMJ Global Health
- Vol. 8 (6) , e012031
WHO should adjust its global strategy for cervical cancer prevention
- 12 June 2023
- Published by BMJ in BMJ Global Health
- Vol. 8 (6) , e012031
Open AccessWHO should adjust its global strategy for cervical cancer prevention
- 10 February 2022
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 386 (6) , 607-608
The IARC Perspective on Cervical Cancer Screening
To the Editor: As discussed by Bouvard et al. (Nov. 11 issue),1 the International Agency for Research on Cancer (IARC), which evaluates screening and treatment strategies for cervical cancer, assigned an “A” rating to the quality of a cluster-randomized, controlled trial conducted in Mumbai, India.2 Reportedly, the Mumbai trial assessed the effectiveness of visual inspection with acetic acid (VIA) for cervical cancer screening as compared with no screening.1,2 However, documents obtained through the U.S. Freedom of Information Act established that the Mumbai trial assessed the effectiveness of unaided visual inspection, a cervical cancer screening test that cannot detect precancerous cervical lesions . . .
- 10 February 2022
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 386 (6) , 607-608
The IARC Perspective on Cervical Cancer Screening
To the Editor: As discussed by Bouvard et al. (Nov. 11 issue),1 the International Agency for Research on Cancer (IARC), which evaluates screening and treatment strategies for cervical cancer, assigned an “A” rating to the quality of a cluster-randomized, controlled trial conducted in Mumbai, India.2 Reportedly, the Mumbai trial assessed the effectiveness of visual inspection with acetic acid (VIA) for cervical cancer screening as compared with no screening.1,2 However, documents obtained through the U.S. Freedom of Information Act established that the Mumbai trial assessed the effectiveness of unaided visual inspection, a cervical cancer screening test that cannot detect precancerous cervical lesions . . .
- 1 December 2017
- Published by Elsevier in Preventive Medicine
- Vol. 105, 357-358
Correspondence regarding Castle., Human papillomavirus screening for low and middle-income countries
- 1 December 2017
- Published by Elsevier in Preventive Medicine
- Vol. 105, 357-358
Correspondence regarding Castle., Human papillomavirus screening for low and middle-income countries
- 1 July 2017
- Published by Elsevier in Preventive Medicine
- Vol. 100, 296
Human papillomavirus screening for low and middle-income countries
- 1 July 2017
- Published by Elsevier in Preventive Medicine
- Vol. 100, 296
Human papillomavirus screening for low and middle-income countries
- RetractedOpen Access
- 1 March 2017
- Published by BMJ in BMJ Global Health
- Vol. 2 (2) , e000177
Unethical randomised controlled trial of cervical screening in India: US Freedom of Information Act disclosures
This paper has been withdrawn. After acceptance it was inadvertently published online while awaiting legal review. It has now been withdrawn on legal advice. For the official publisher note please see: http://gh.bmj.com/content/2/2/bmjgh-2016-000177notice
- 1 March 2017
- Published by BMJ in BMJ Global Health
- Vol. 2 (2) , e000177
RetractedOpen AccessUnethical randomised controlled trial of cervical screening in India: US Freedom of Information Act disclosures
This paper has been withdrawn. After acceptance it was inadvertently published online while awaiting legal review. It has now been withdrawn on legal advice. For the official publisher note please see: http://gh.bmj.com/content/2/2/bmjgh-2016-000177notice
- 1 July 2014
- Published by Forum for Medical Ethics Society in Indian Journal of Medical Ethics
US-funded measurements of cervical cancer death rates in India: scientific and ethical concerns
US-funded measurements of cervical cancer death rates in India: scientific and ethical concerns
- 1 July 2014
- Published by Forum for Medical Ethics Society in Indian Journal of Medical Ethics
US-funded measurements of cervical cancer death rates in India: scientific and ethical concerns
US-funded measurements of cervical cancer death rates in India: scientific and ethical concerns
- 6 June 2014
- Published by Forum for Medical Ethics Society in Indian Journal of Medical Ethics
Response by Eric Suba to Sankaranarayanan et al
Response by Eric Suba to Sankaranarayanan et al
- 6 June 2014
- Published by Forum for Medical Ethics Society in Indian Journal of Medical Ethics
Response by Eric Suba to Sankaranarayanan et al
Response by Eric Suba to Sankaranarayanan et al
- 1 May 2014
- Published by Elsevier in The Lancet
- Vol. 383 (9931) , 1804
Cervical cancer mortality in India
- 1 May 2014
- Published by Elsevier in The Lancet
- Vol. 383 (9931) , 1804
Cervical cancer mortality in India